Adaptive Biotechnologies (ADPT) Depreciation & Amortization (CF) (2018 - 2026)

Adaptive Biotechnologies has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $3.4 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $3.4 million, down 21.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.1 million (down 11.0% YoY), and the FY2025 annual result was $16.0 million, down 8.26% from the prior year.
• Depreciation & Amortization (CF) came in at $3.4 million for Q1 2026 at Adaptive Biotechnologies, down from $3.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.3 million in Q3 2023 to a low of $3.4 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $4.6 million (2022), against an average of $4.5 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 105.91% in 2022 and declined 22.1% in 2024, its largest moves.
• Adaptive Biotechnologies' Depreciation & Amortization (CF) stood at $4.9 million in 2022, then advanced by 2.18% to $5.0 million in 2023, then retreated by 20.79% to $3.9 million in 2024, then decreased by 7.1% to $3.7 million in 2025, then dropped by 7.28% to $3.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $3.4 million (Q1 2026), $3.7 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.